Craig Curtis
Lou Ruvo Brain Institute
9 Papers
14 Citations
Craig Curtis is an academic researcher from Lou Ruvo Brain Institute. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
Adam S. Fleisher,Michael J. Pontecorvo,Michael D. Devous,Ming Lu,Anupa Arora,Stephen P Truocchio,Patricia Aldea,Matthew Flitter,Tricia Locascio,Marybeth Devine,Andrew Siderowf,Thomas G. Beach,Thomas J. Montine,Geidy E. Serrano,Craig Curtis,Allison Perrin,Stephen Salloway,Misty Daniel,Charles Wellman,Abhinay D. Joshi,David J. Irwin,Val J. Lowe,William W. Seeley,Milos D. Ikonomovic,Joseph C. Masdeu,Ian Kennedy,Thomas S. Harris,Michael Navitsky,Sudeepti Southekal,Mark A. Mintun,A Study Investigators +30 more
TL;DR: The findings suggest that PET imaging with [18F]flortaucipir could be used to identify the density and distribution of AD-type tau pathology and the presence of high levels of AD neuropathological change.
Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density
Craig Curtis,Jose Gamez,Upinder Singh,Carl H. Sadowsky,Teresa Villena,Marwan N. Sabbagh,Thomas G. Beach,Ranjan Duara,Adam S. Fleisher,Adam S. Fleisher,Kirk A. Frey,Zuzana Walker,Zuzana Walker,Arvinder Hunjan,Clive Holmes,Yavir M. Escovar,Carla X. Vera,Marc Agronin,Joel Ross,Andrea Bozoki,Mary Akinola,Jiong Shi,Rik Vandenberghe,Milos D. Ikonomovic,Paul Sherwin,Igor D. Grachev,Igor D. Grachev,G. Farrar,Adrian Smith,Christopher Buckley,Richard McLain,Stephen Salloway,Stephen Salloway +32 more
TL;DR: This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population and may increase diagnostic accuracy in cognitively impaired patients.
284
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Vladimir Coric,Stephen Salloway,Christopher H. van Dyck,Bruno Dubois,Niels Andreasen,Mark Brody,Craig Curtis,Hilkka Soininen,Stephen G. Thein,Thomas Shiovitz,Gary Pilcher,Steven H. Ferris,Susan Colby,Wendy Kerselaers,Randy C. Dockens,Holly Soares,Stephen Kaplita,Feng Luo,Chahin Pachai,Luc Bracoud,Mark A. Mintun,Joshua D. Grill,Ken Marek,John Seibyl,Jesse M. Cedarbaum,Charles F. Albright,Howard Feldman,Robert M. Berman +27 more
TL;DR: Avagacestat did not demonstrate efficacy and was associated with adverse dose-limiting effects in this PDAD population, which had higher rates of clinical progression to dementia and greater brain atrophy compared with CSF biomarker-negative participants.
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Jeffrey L. Cummings,Sharon Cohen,Christopher H. van Dyck,Mark Brody,Craig Curtis,William Cho,Michael Ward,Michel Friesenhahn,Christina Rabe,Flavia Brunstein,Angelica Quartino,Lee A. Honigberg,Reina N. Fuji,David Clayton,Deborah Mortensen,Carole Ho,Robert Paul +16 more
TL;DR: This study provides Class II evidence that, for people with AD, crenezumab does not significantly improve cognition or function at 18 months, and data support the exploration of creneZumab treatment at even higher doses in patients with early AD.
204
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials.
Ming Lu,Michael Pontecorvo,Michael D. Devous,Anupa Arora,Nicholas Galante,Anne McGeehan,Catherine Devadanam,Stephen Salloway,Stephen Salloway,P. Murali Doraiswamy,Craig Curtis,Stephen P. Truocchio,Matthew Flitter,Tricia Locascio,Marybeth Devine,Jennifer A. Zimmer,Adam S. Fleisher,Mark A. Mintun +17 more
TL;DR: In this article, the authors evaluated the association between flortaucipir PET visual interpretation and patients' near-term clinical progression and found that the interpretation may provide valuable information regarding the risk of clinical deterioration over 18 months among patients with Alzheimer disease (AD) or mild cognitive impairment (MCI).